FDA approves combination therapy for higher-risk clear cell kidney cancer after surgery

by Dana-Farber Cancer Institute

edited by Sadie Harley, reviewed by Andrew Zinin

Sadie Harley

Scientific Editor

Meet our editorial team
Behind our editorial process

Andrew Zinin

Lead Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

trusted source

proofread

The GIST Add as preferred source

The U.S. Food and Drug Administration (FDA) has approved pembrolizumab, an immunotherapy, plus belzutifan, a HIF-2α inhibitor, as adjuvant treatment for adult patients with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, with or without resection of metastatic lesions.

The approval is based on results from the Phase III LITESPARK-022 trial, led by Toni Choueiri, MD, director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute.

"This approval establishes this combination of pembrolizumab and belzutifan as a new adjuvant option for patients with ccRCC at increased risk of recurrence," said Choueiri. "Because surgery alone is not enough for many patients, a meaningful proportion will relapse, often with metastatic disease. This combination provides a more effective strategy to reduce the likelihood of the cancer returning than pembrolizumab alone."

This is the first approval for belzutifan in earlier-stage ccRCC and the first approval for a PD-1 and HIF-2α inhibitor combination regimen. The FDA also approved the subcutaneous combination of pembrolizumab and berahyaluronidase alfa-pmph plus belzutifan.

The LITESPARK-022 study, presented by Choueiri at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium, included 1,841 participants with ccRCC. Participating patients underwent surgery to remove the tumor and had no signs of cancer but had an elevated risk of recurrence.

Patients were randomized to receive either pembrolizumab plus belzutifan after surgery or pembrolizumab plus placebo after surgery.

With a median follow-up of 28.4 months, the combination of pembrolizumab plus belzutifan resulted in a 28% decrease in the risk of recurrence, metastasis or death.

About 81% of participants who took the two-drug regimen were cancer-free after an estimated 24 months, compared with 74% of those who received the standard-of-care regimen of pembrolizumab plus placebo. Side effects were consistent with data from previously reported studies.

The HIF-2α inhibitor belzutifan helps reduce the risk of progression by blocking HIF-2α, which is overabundant in ccRCC cells and drives cancer growth. Dana-Farber's William G. Kaelin Jr., MD, was awarded a Nobel Prize in Physiology or Medicine in 2019 for the science behind the development of belzutifan.

Renal cell carcinoma (RCC) is the most common type of kidney cancer, with about nine out of 10 kidney cancer diagnoses being RCC.

In 2022, there were about 435,000 new cases of kidney cancer diagnosed and approximately 156,000 deaths from the disease worldwide. Clear cell renal cell carcinoma, which accounts for 75% of RCC diagnoses, is the most common subtype. About 30% of patients with ccRCC experience disease recurrence within five years following nephrectomy.

Key medical concepts

Hypernephroid Carcinomapembrolizumabbelzutifan

Clinical categories

OncologyUrology Provided by Dana-Farber Cancer Institute Who's behind this story?

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: FDA approves combination therapy for higher-risk clear cell kidney cancer after surgery (2026, June 15) retrieved 15 June 2026 from https://medicalxpress.com/news/2026-06-fda-combination-therapy-higher-cell.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.